Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Regulation

FDA answers urgent call for DMD gene therapy despite controversy, consequences

FDA’s approval of Elevidys is likely to please patients but fuel a firestorm over accelerated approval, and open a pandora’s box of problems on access for gene therapies

June 22, 2023 11:50 PM UTC

The landmark accelerated approval of Elevidys from Sarepta to treat Duchenne muscular dystrophy is a major milestone and beacon of hope for patients and families, but it’s also an approval that’s bound to shine light on the healthcare system’s lack of readiness for delivering new gene therapies to patients — an issue that will continue to impact launches for companies and timely access to gene therapies for patients. 

The decision to grant accelerated approval, particularly for a narrow age window, will also have consequences for the patients who currently are in the eligibility window, on future gene therapy development, and on confidence in the scientific rigor of FDA decision-making. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article